Peginterferon Lambda

Status
Phase 2
Condition
COVID-19
Intervention Type
Subcutaneous (SC) Injection
Funder Type
Industry

Drug Details

Peginterferon Lambda is a well-characterized, late-stage, first-in-class, type III interferon (IFN) that stimulates immune responses that are critical for the development of host protection during viral infections.   

Study Purpose

This is a phase 2b prospective, randomized, single-blind, controlled trial of two weekly subcutaneous injections of lambda interferon alfa-1a versus placebo for prevention of SARS-CoV-2 infection in non-hospitalized participants at high risk for infection due to household exposure to an individual with coronavirus disease (COVID-19).

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >